Skip to main content

Table 2 Baseline characteristics of AFLP patients received PE or not

From: The assessment in patients with acute fatty liver of pregnancy (AFLP) treated with plasma exchange: a cohort study of 298 patients

 

GROUP A

PE

(n = 79)

GROUP B

NO PE

(n = 211)

P value

aP value

Maternal age at first AFLP pregnancy, y, (mean ± SD)

26.86 ± 3.63

27.32 ± 5.37

0.38

0.11

BMI, Kg/m2, (mean ± SD)

23.71 ± 3.69

24.18 ± 3.22

0.50

0.89

Gravidity, (mean ± SD)

1.71 ± 0.76

1.68 ± 0.84

0.72

0.69

Multiparae

8(10.13%)

49(23.22%)

0.01

0.50

Fetal sex male

54(68.35%)

179(84.83%)

 < 0.01

0.72

Gestational age, d, (mean ± SD)

241.43 ± 16.56

256.82 ± 16.54

0.78

0.10

Multiplets

19(24.05%)

6(2.84%)

 < 0.01

0.77

Days from symptom onset to hospitalization, d, (mean ± SD)

9.80 ± 7.05

14.89 ± 20.00

0.41

0.55

Days from symptom onset to parturition, d, (mean ± SD)

10.80 ± 6.22

16.26 ± 20.53

0.30

0.57

APACHEII score, (mean ± SD)

19.75 ± 10.87

17.00 ± 9.04

0.97

0.16

Swansea score, (mean ± SD)

7.86 ± 1.35

7.41 ± 1.53

0.71

0.07

Complications

 Hypertension before pregnancy

2(2.53%)

5(2.37%)

0.99

0.99

 Preeclampsia

15(18.99%)

39(18.48%)

0.99

0.54

 Hypothyroidism during pregnancy

1(1.27%)

5(2.84%)

0.68

0.32

 Gestational diabetes

5(6.33%)

12(5.69%)

0.79

0.66

 Encephalopathy

22(27.85%)

59(27.96%)

0.99

0.27

 Infection

11(13.92%)

49(23.22%)

0.10

0.25

 Postpartum Hemorrhage

8(10.13%)

31(14.69%)

0.34

0.89

 HELLP syndrome

16(20.25%)

18(8.53%)

0.01

0.67

 Placenta previa

17(21.52%)

16(7.58%)

 < 0.01

0.56

 Placental Abruption

11(13.92%)

28(13.27%)

0.85

0.76

 Fetal distress

33(41.77%)

97(45.97%)

0.60

0.50

 Fetal death

22(27.85%)

56(26.54%)

0.88

0.72

 Others

3(3.80%)

16(7.58%)

0.30

0.45

Lab on first visit (mean ± SD)

 Hemoglobin(g/L)

112.43 ± 26.66

111.86 ± 25.43

0.62

0.17

 Platelet (*109/L)

145.71 ± 81.71

140.36 ± 81.99

0.99

0.09

 TBil (mmol/L)

202.03 ± 107.10

139.64 ± 94.59

0.86

0.88

 DBil (mmol/L)

175.16 ± 95.80

118.44 ± 91.64

0.81

0.88

 ALT (IU/L)

160.86 ± 158.22

363.50 ± 748.94

0.37

0.45

 PT (s)

34.57 ± 38.01

18.65 ± 6.25

 < 0.01

0.39

 APTT(s)

53.77 ± 15.23

47.78 ± 17.30

0.68

0.22

 Prothrombin activity (%)

41.93 ± 10.06

50.91 ± 19.80

0.07

0.64

 Scr (umol/L)

225.14 ± 39.38

179.82 ± 82.59

0.052

0.68

 BUN (mmol/L)

8.77 ± 5.82

7.06 ± 3.01

0.07

0.08

 WBC(*106/L)

17.45 ± 9.11

15.28 ± 5.07

 < 0.01

0.10

 Trioxypurine (μmol/L)

391.14 ± 144.48

350.91 ± 152.23

0.63

0.69

Management

 Bilirubin adsorption

20(25.32%)

2(0.95%)

 < 0.01

NA

 CRRT

66(83.54%)

41(19.43%)

 < 0.01

NA

 Cesarean section

77(97.47%)

190(90.05%)

0.04

0.53

 Hysterectomy

13(16.5%)

21(9.9%)

0.43

0.52

  1. Data are presented as the number (percentage) of patients unless indicated otherwise
  2. AFLP Acute fatty liver of pregnancy, PE Plasma exchange, BMI Body Mass Index, APACHEII score Acute Physiology and Chronic Health Evaluation, TBil Total bilirubin, DBil Direct bilirubin, ALT Alanine transaminase, PT Prothrombin time, APTT Activated partial thromboplastin time, Scr Serum creatinine, BUN Blood urea nitrogen, WBC White blood cells, CRRT Renal replacement therapy
  3. aOf 290 patients, 79 pairs were matched